Management of Clostridioides difficile Infection

Rationale for Avoiding Metoclopramide in C. diff Infection

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) explicitly recommends that antiperistaltic agents should be avoided in C. difficile infection (strong recommendation, moderate quality evidence) 1

For initial episodes of C. difficile infection, either vancomycin (125 mg orally four times daily) or fidaxomicin (200 mg twice daily) for 10 days is now recommended over metronidazole, as suggested by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines based on high-quality evidence 2
The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines recommend vancomycin 125 mg four times daily or fidaxomicin 200 mg twice daily for 10 days for non-severe C. difficile infection 2
For severe C. difficile infection, vancomycin 125 mg four times daily or fidaxomicin 200 mg twice daily for 10 days is recommended, with closer monitoring 2
For fulminant C. difficile infection, vancomycin 500 mg four times daily orally plus intravenous metronidazole 500 mg every 8 hours is recommended 2

Discontinue the inciting antibiotic as soon as possible to reduce the risk of recurrence, as recommended by the Infectious Diseases Society of America (IDSA) 2
Metronidazole is now only recommended when access to vancomycin or fidaxomicin is limited, and only for non-severe initial episodes, according to the Infectious Diseases Society of America (IDSA) 2
Avoid prolonged or repeated courses of metronidazole due to the risk of cumulative and potentially irreversible neurotoxicity, as warned by the Infectious Diseases Society of America (IDSA) 2

If symptomatic relief of diarrhea is needed in C. difficile infection, focus on appropriate antibiotic therapy rather than adding antimotility agents, as suggested by the Infectious Diseases Society of America (IDSA) 2
For patients already on metoclopramide for other indications, consider temporarily discontinuing it during C. difficile treatment, as recommended by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 1
Prioritize appropriate antibiotic therapy with either vancomycin or fidaxomicin, which have been shown to be superior to metronidazole in clinical outcomes, according to the Infectious Diseases Society of America (IDSA) 2

The Infectious Diseases Society of America recommends against opening vancomycin capsules as a standard practice due to stability concerns and lack of guideline support, suggesting this is not a recommended approach for patients with difficulty swallowing 3
The American College of Gastroenterology suggests that opening capsules risks inaccurate dosing, particularly critical given that vancomycin for C. difficile requires precise 125 mg four times daily dosing for optimal outcomes 3

The Society for Healthcare Epidemiology of America recommends that intravenous vancomycin formulations can be administered orally when capsules cannot be swallowed, though you must verify the specific IV formulation's package insert confirms this is an approved indication 3
The Infectious Diseases Society of America explicitly recognizes that not all intravenous formulations of vancomycin can be given orally and it is advised to refer to the medication package inserts to ascertain approved indications before use, with intravenous vancomycin given orally being an option when oral capsular form of vancomycin is not available 3

The American College of Gastroenterology recommends maintaining the standard 125 mg four times daily for 10 days for C. difficile infection, whether using IV formulation orally or oral solution 3
For fulminant cases of C. difficile infection, the Infectious Diseases Society of America recommends increasing to 500 mg four times daily orally plus intravenous metronidazole 500 mg every 8 hours 3

The Society for Healthcare Epidemiology of America advises against assuming all IV vancomycin products are approved for oral use, as this varies by manufacturer and must be verified in the package insert before administration 3